10x Genomics gets injunction against Parse Biosciences' ATAC Products
Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement was ...
Business Wire1mon
Parse Biosciences Invalidates All 10x Genomics’ Patent Claims Asserted Against Its Products
Coupled with the invalidation of 10x Genomics’ 10,155,981 patent last ... but rather described an unrelated method. “We are pleased with the decision published by the Patent Trial and Appeal ...
10x Genomics secures injunction against Parse Biosciences’ planned ATAC products
Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...
Nasdaq16d
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and infringed by Parse's use of ATAC-seq methods and compositions. "This development further ...